Yoshinori Sasaki

Tokyo Medical University, Edo, Tōkyō, Japan

Are you Yoshinori Sasaki?

Claim your profile

Publications (2)1.96 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: We report a case of postoperative recurrence of liposarcoma of the mesenterium successfully treated by chemotherapy using ifosfamide (IFM) and cisplatin (CDDP). A 58-year-old man presented with a strange feeling in the lower abdomen. Enhanced computed tomography showed enhanced non-epithelial tumor in the pelvic space. The tumor moved on palpation, so we diagnosed liposarcoma from the mesenterium, and resected the tumor on 22 August, 2002. The pleomorphic liposarcoma was 11 x 14 x 7 cm, growing from the mesenterium of the sigmoid colon, and weighed 640 g. We performed re-operation due to pelvic recurrence on 24 March, 2003. On 18 September of the same year, when we performed re-operation again for pelvic recurrence, there were so many recurrences on the mesenterium of small intestine that resection was impossible. We started chemotherapy 3 days later using 3.0 g/body IFM from 1 October 2003, together with 1,800 mg/body mesna for prevention of hemorrhage cystitis. We continued chemotherapy using 3.0 g/body/day IFM together with 1, 800 mg/body/day mesna on an outpatient basis, upon his weekly visit to the hospital. Patient remission was shown by abdominal enhanced computed tomography on 10 December. Some grade 2 alopecia and grade 2 leukopenia occurred, so we changed to chemotherapy once every two weeks. Then, it continued to decrease, without any side effects. The response appeared to be complete on computed tomography in August 2004, and we have been continuing the same chemotherapy without recurrence.
    Gan to kagaku ryoho. Cancer & chemotherapy 06/2006; 33(5):679-82.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The potential role in cell growth of Macrophage migration inhibitory factor (MIF) has been studied, however, the mechanism of its anti-tumor effect is poorly understood. Antisense-MIF plasmids were directly injected into colon 26 tumors embedded in the back of mice. Furthermore, the role of MIF in the cell cycle was assessed with regard to retinoblastoma (Rb) protein and transcription factor E2F. Plasmids containing sense- and antisense-MIF genes were transfected into human colon cancer KM12SM cells in vitro. To examine the Rb protein-E2F pathway, plasmids containing each specific cis-acting enhancer for Rb protein and E2F with luciferase reporter genes, pRB-luc and pE2F-luc, respectively, were used. Antisense MIF treatment significantly reduced the tumor size. In vitro cell proliferation was significantly suppressed by the antisense treatment as examined by BrdU uptake. Transcriptions of Rb protein were 8.4x10(3) (RLU), 9.5x10(3) and 24.3x10(3) in the antisense MIF, PBK, and the sense MIF, respectively. As for E2F, transcription activities were 3.8x10(3), 3.6x10(3) and 7.7x10(3), respectively. These results indicate the possibility that MIF may promote tumor growth, in which the activation-inactivation mechanism of the Rb protein-E2F pathway could be profoundly involved.
    International Journal of Molecular Medicine 12/2002; 10(5):579-83. · 1.96 Impact Factor